^
    Back
    Association details:
    Biomarker:PD-L1 elevation + CXCL10 elevation + TNFA elevation
    Cancer:Melanoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    SITC 2021
    Title:

    27 Cytokine signature of PD-1, CXCL10, and TNF-alpha predicts response to nivolumab and ipilimumab

    Published date:
    11/09/2021
    Excerpt:
    Using unsupervised machine learning we identified a cytokine signature of high PD-1, CXCL10, and TNF-alpha to be associated with superior PFS in advanced-stage melanoma patients treated with nivolumab/ipilimumab.
    DOI:
    http://dx.doi.org/10.1136/jitc-2021-SITC2021.027